Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Vaxcyte, Inc.NASDAQ: PCVX

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses declines year over year

Q2 FY2026 other income / expenses of $18.48M fell 69.0% year over year, behind the -37.5% change in trailing-twelve-month other income / expenses. Sequentially, it fell 26.8% from the prior quarter. Over 3 fiscal years it compounded at +161.6% a year.

Context

  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -69.0% toward the trailing-twelve-month pace of -37.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$18.48M-26.8% QoQ
Last fiscal yearDec 2025
$157.05M+48.7% YoY
LTMJun 2026
$101.03M-37.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.0%——
1 year+48.7%——
3-year CAGR+161.6%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
157.05M USD
Year-over-year change
+48.7%
4-year CAGR
+157.1%

Other Income / Expenses vs competitors

How PCVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.5% is the 3rd highest of 9, against a peer median of -101.2%.
  • Over three fiscal years its annual growth of +161.6% compares with a peer median of +25.4%.
PCVX Competitors
Other Income / Expenses for PCVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$201M USD-35.2%+25.4%8.0%
PCVXVaxcyte, Inc.LTM Jun 2026$101.03M USD-37.5%+161.6%—
VIRVir Biotechnology, Inc.LTM Mar 2026$19.31M USD-71.4%—29.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$10.54M USD-22.0%—23.2%
NVAXNovavax, Inc.LTM Mar 2026-$19.43M USD-125.2%—3.3%
VALNValneva SELTM Mar 2026-€38.24M EUR-120.8%—24.5%
IBRXImmunityBio, Inc.LTM Sep 2026-$835.68M USD-850.2%—457.7%
GSKGSK plcLTM Jun 2026-£969M GBP-93.0%—2.9%
PFEPfizer Inc.LTM Jun 2026-$12.81B USD-109.5%—20.1%
Peer median (excluding PCVX) —-101.2%+25.4%21.7%

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development78.41M169.45M332.34M476.64M794.31M
Selling, General & Admin25.26M39.81M60.7M92.9M129.37M
Operating Expenses103.67M232.26M468.04M569.55M923.68M
Depreciation & Amortization3.46M9.45M10.17M15.85M24.86M
EBITDA(96.61M)(214.03M)(392.1M)(448.08M)(741.77M)
EBITDA Margin—————
Operating Income(103.67M)(232.26M)(468.04M)(569.55M)(923.68M)
Operating Margin—————
Interest Income344K8.36M62.91M109.99M119.72M
Interest Expense7K2K000
Other Income / Expenses3.59M8.77M65.78M105.62M157.05M
Income Before Tax(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Net Margin—————
EPS (Basic)(1.93)(3.44)(4.14)(3.80)(5.63)
EPS (Diluted)(1.93)(3.44)(4.14)(3.80)(5.63)
Weighted Avg Shares51.92M64.88M97.16M122M136.09M
Weighted Avg Shares (Diluted)51.92M64.88M97.16M122M136.09M

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.